FRANKFURT (Reuters) – Germany’s Merck KGaA said that experimental cancer drug evofosfamide, which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic …read more
Source:: UKScienceNews